Skip Navigation



Brain Advance Access published online on November 5, 2009
Brain, doi:10.1093/brain/awp275
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Greenberg, S. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, S. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on alemtuzumab and inclusion body myositis

Steven A. Greenberg

Harvard Medical School, Brigham and Women's Hospital Neurology, Boston, MA, USA

Correspondence to: Steven A Greenberg, MD, Harvard Medical School, Brigham and Women's Hospital Neurology, 75 Francis Street, Boston, MA 02115, USA E-mail: sagreenberg@partners.org

The first 150 words of the full text of this article appear below.

Sir, The recent Brain publication (Dalakas et al., 2009Go) describing a clinical study of alemtuzumab in patients with inclusion body myositis nicely demonstrates the feasibility of enrolling and following a cohort of these patients over a long period of time as participants in an intervention study. The authors state that ‘in [inclusion body myositis] one series of alemtuzumab infusions can slow down disease progression up to 6 months’. Prior to publication of this paper in Brain, two scientific meeting abstracts and an editorial similarly reported results of this study as showing that, in inclusion body myositis, alemtuzumab may have a role in improving the clinical condition of patients (Dalakas et al., 2007aGo, bGo; Dalakas, 2008Go). Based on the Methods and Results now published in Brain, I have concerns that these conclusions may require further analysis for several reasons.

  1. According . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?